| TOTAL | $7.78M |
| VENTURE FUNDING TOTAL | $7.78M |
| Series A, 5/11 Flagship Ventures Polaris Venture Partners Third Rock Ventures | $4.5M |
| Grant, 12/11 The Bill & Melinda Gates Foundation | $3.28M |
| DEBT TOTAL | $750k |
| Debt, 4/12 | $750k |
Seventh Sense Biosystems is developing novel products to optimize the interface of diagnostic medicine and the healthcare consumer by dramatically simplifying blood sampling and testing. By eliminating the barriers to the acquisition of critical diagnostic information, Seventh Sense is contributing to the future of informed, effective healthcare delivery and patient participation in their own well-being. The Seventh Sense On Vivo™ platform will enable diagnostic testing to be performed safely and painlessly by virtually anyone, anywhere. Their proprietary, single-step Touch Activated Phlebotomy™ (TAP™) technology can be combined with a variety of diagnostic assays for rapid results. TAP’s revolutionary sampling capabilities may also integrate with analytical systems to vastly improve the patient and clinician experience.
